Ambalal Sarabhai Enterprises Ltd vs Emcure Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Ambalal Sarabhai Enterprises Ltd is ₹ 31.33 as of 05 May 15:30 . The P/E Ratio of Ambalal Sarabhai Enterprises Ltd changed from 4.6 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 64.14% over 5 yearsThe P/E Ratio of Emcure Pharmaceuticals Ltd changed from 29.8 on March 2025 to 29.8 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Ambalal Sarabhai Enterprises Ltd changed from ₹ 135.26 crore on March 2021 to ₹ 268.6 crore on March 2025 . This represents a CAGR of 14.71% over 5 yearsThe Market Cap of Emcure Pharmaceuticals Ltd changed from ₹ 20327 crore on March 2025 to ₹ 20327 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Ambalal Sarabhai Enterprises Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 54.76 crore. This represent the decline of -100% The revenue of Emcure Pharmaceuticals Ltd for the Mar '26 is ₹ 2484 crore as compare to the Dec '25 revenue of ₹ 2365 crore. This represent the growth of 5.02% The ebitda of Ambalal Sarabhai Enterprises Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 6.02 crore. This represent the decline of -100% The ebitda of Emcure Pharmaceuticals Ltd for the Mar '26 is ₹ 493.84 crore as compare to the Dec '25 ebitda of ₹ 456.45 crore. This represent the growth of 8.19% The net profit of Ambalal Sarabhai Enterprises Ltd changed from ₹ 0.35 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Emcure Pharmaceuticals Ltd changed from ₹ 152.59 crore to ₹ 243.74 crore over 8 quarters. This represents a CAGR of 26.39% The Dividend Payout of Ambalal Sarabhai Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Emcure Pharmaceuticals Ltd changed from 4.3 % on March 2021 to 17.92 % on March 2025 . This represents a CAGR of 33.04% over 5 years .

About Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Limited, incorporated on June 27, 1977, houses a range of companies across multi-dimensional businesses.
It is one of the oldest pharmaceutical health care companies in India, and through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally. The Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments.
Pharmaceuticals segment is engaged in manufacture of drugs and formulations.
Electronics segment is engaged in manufacture of electronics instruments and services. In 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections. During the year 1997-98, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company.

About Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay.
Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001. Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.

FAQs for the comparison of Ambalal Sarabhai Enterprises Ltd and Emcure Pharmaceuticals Ltd

Which company has a larger market capitalization, Ambalal Sarabhai Enterprises Ltd or Emcure Pharmaceuticals Ltd?

Market cap of Ambalal Sarabhai Enterprises Ltd is 240 Cr while Market cap of Emcure Pharmaceuticals Ltd is 32,068 Cr

What are the key factors driving the stock performance of Ambalal Sarabhai Enterprises Ltd and Emcure Pharmaceuticals Ltd?

The stock performance of Ambalal Sarabhai Enterprises Ltd and Emcure Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ambalal Sarabhai Enterprises Ltd and Emcure Pharmaceuticals Ltd?

As of May 5, 2026, the Ambalal Sarabhai Enterprises Ltd stock price is INR ₹31.33. On the other hand, Emcure Pharmaceuticals Ltd stock price is INR ₹1691.45.

How do dividend payouts of Ambalal Sarabhai Enterprises Ltd and Emcure Pharmaceuticals Ltd compare?

To compare the dividend payouts of Ambalal Sarabhai Enterprises Ltd and Emcure Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.